2.75
+0.1624(+6.27%)
Currency In USD
| Previous Close | 2.59 |
| Open | 2.6 |
| Day High | 2.75 |
| Day Low | 2.6 |
| 52-Week High | 4.39 |
| 52-Week Low | 1.75 |
| Volume | 48,741 |
| Average Volume | 44,565 |
| Market Cap | 232.55M |
| PE | -6.12 |
| EPS | -0.45 |
| Moving Average 50 Days | 2.64 |
| Moving Average 200 Days | 2.65 |
| Change | 0.16 |
If you invested $1000 in Alpha Tau Medical Ltd. (DRTS) since IPO date, it would be worth $268.32 as of May 07, 2025 at a share price of $2.71. Whereas If you bought $1000 worth of Alpha Tau Medical Ltd. (DRTS) shares 3 years ago, it would be worth $384.94 as of May 07, 2025 at a share price of $2.71.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Alpha Tau to Participate in May Investor Conferences
GlobeNewswire Inc.
Yesterday at 12:30 PM GMT
JERUSALEM, May 06, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will presentat
Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals
GlobeNewswire Inc.
Apr 28, 2025 1:00 PM GMT
Investment comes at a pivotal moment for Alpha Tau, which is experiencing remarkable growth on multiple fronts, with four active U.S. trial approvals, expansion into multiple internal organ applications, scaling up of manufacturing capabilities, and
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma
GlobeNewswire Inc.
Apr 02, 2025 12:30 PM GMT
JERUSALEM, April 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that the FDA has approved an Investigational Device Exemption (I